D.E. Shaw & Co
XERS icon

D.E. Shaw & Co’s Xeris Biopharma Holdings XERS Stock Holding History

D.E. Shaw & Co’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.2M Buy
7,788,811
+213,961
+3% +$1.42M 0.03% 704
2025
Q4 		$59.5M Buy
7,574,850
+1,734,964
+30% +$13.7M 0.03% 631
2025
Q3 		$47.5M Buy
5,839,886
+2,004,479
+52% +$13.3M 0.03% 685
2025
Q2 		$17.9M Buy
3,835,407
+783,035
+26% +$3.59M 0.01% 1105
2025
Q1 		$16.8M Buy
3,052,372
+1,688,920
+124% +$6.82M 0.01% 1050
2024
Q4 		$4.62M Buy
1,363,452
+378,437
+38% +$1.22M ﹤0.01% 2044
2024
Q3 		$2.81M Buy
985,015
+466,991
+90% +$1.2M ﹤0.01% 2429
2024
Q2 		$1.17M Sell
518,024
-188,987
-27% -$381K ﹤0.01% 3084
2024
Q1 		$1.56M Sell
707,011
-347,599
-33% -$899K ﹤0.01% 2804
2023
Q4 		$2.48M Buy
1,054,610
+179,200
+20% +$331K ﹤0.01% 2504
2023
Q3 		$1.63M Buy
875,410
+149,359
+21% +$342K ﹤0.01% 2727
2023
Q2 		$1.9M Buy
726,051
+593,872
+449% +$1.51M ﹤0.01% 2661
2023
Q1 		$215K Sell
132,179
-30,200
-19% -$37.8K ﹤0.01% 3874
2022
Q4 		$216K Buy
162,379
+5,124
+3% +$7.23K ﹤0.01% 4215
2022
Q3 		$245K Buy
157,255
+108,392
+222% +$179K ﹤0.01% 4390
2022
Q2 		$75K Sell
48,863
-100,183
-67% -$211K ﹤0.01% 4776
2022
Q1 		$382K Buy
+149,046
New +$364K ﹤0.01% 4526
2021
Q3 		– Sell
-261,488
Closed -$1.06M – 5277
2021
Q2 		$1.06M Sell
261,488
-723,828
-73% -$2.76M ﹤0.01% 3482
2021
Q1 		$4.44M Buy
985,316
+91,718
+10% +$495K ﹤0.01% 1939
2020
Q4 		$4.4M Buy
893,598
+57,301
+7% +$287K ﹤0.01% 1969
2020
Q3 		$4.96M Buy
836,297
+335,117
+67% +$1.34M 0.01% 1697
2020
Q2 		$1.33M Buy
501,180
+19,163
+4% +$66.7K ﹤0.01% 2724
2020
Q1 		$940K Buy
+482,017
New +$2.07M ﹤0.01% 2776

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co's XERS Position: Q1 2026 in Review

D.E. Shaw & Co increased its Xeris Biopharma Holdings (XERS) stake by 2.8% in Q1 2026, buying an estimated $1.42M and bringing the position to 7,788,811 shares worth $45.2M. The position accounts for 0.03% of the portfolio, ranked #704.

D.E. Shaw & Co first reported a position in XERS in Q1 2020 and has held it in 23 quarters since. The position peaked at $59.5M in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • D.E. Shaw & Co held 7,788,811 shares of Xeris Biopharma Holdings worth $45.2M as of Q1 2026.
  • D.E. Shaw & Co bought 213,961 Xeris Biopharma Holdings shares in Q1 2026, an estimated $1.42M.
  • Xeris Biopharma Holdings made up 0.03% of D.E. Shaw & Co's portfolio in Q1 2026, its #704 holding.
  • D.E. Shaw & Co first reported a position in Xeris Biopharma Holdings in Q1 2020 and has held it in 23 quarters since.
  • D.E. Shaw & Co's Xeris Biopharma Holdings position peaked at $59.5M in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.